Trade Report: Today, Pfizer’s (PFE) Buy Rating Reaffirm at Bank of America Corp.

Today, Pfizer’s (PFE) Buy Rating Reaffirm at Bank of America Corp.

Pfizer Inc. (NYSE:PFE)‘s stock had its “buy” rating reissued by equities research analysts at Bank of America Corp. in a research note issued on Monday. They currently have a $36.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $40.00. Bank of America Corp.’s price target would suggest a potential upside of 13.60% from the company’s current price.

A number of other equities analysts have also commented on PFE. Jefferies Group set a $41.50 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday, July 14th. Vetr lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $37.97 price objective for the company. in a research report on Thursday, July 14th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, July 20th. BMO Capital Markets restated a “buy” rating and issued a $40.00 price objective on shares of Pfizer in a research report on Thursday, July 21st. Finally, JPMorgan Chase & Co. set a $40.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 25th. Thirteen analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $37.73.

Pfizer (NYSE:PFE) traded up 0.86% during midday trading on Monday, reaching $31.69. 10,452,948 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $32.01 and a 200-day moving average of $34.15. Pfizer has a 12 month low of $28.25 and a 12 month high of $37.39. The stock has a market cap of $192.31 billion, a PE ratio of 31.82 and a beta of 0.90.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $0.61 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by $0.01. Pfizer had a net margin of 13.09% and a return on equity of 23.68%. The firm earned $13.05 billion during the quarter, compared to the consensus estimate of $13.05 billion. During the same quarter last year, the business posted $0.60 earnings per share. Pfizer’s revenue was up 7.9% compared to the same quarter last year. On average, equities research analysts predict that Pfizer will post $2.41 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be paid a $0.30 dividend. This represents a $1.20 annualized dividend and a dividend yield of 3.79%. The ex-dividend date is Tuesday, November 8th. Pfizer’s payout ratio is 106.20%.

In related news, insider Albert Bourla sold 18,390 shares of Pfizer stock in a transaction on Friday, November 4th. The shares were sold at an average price of $30.05, for a total value of $552,619.50. Following the transaction, the insider now directly owns 149,199 shares of the company’s stock, valued at $4,483,429.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Anthony J. Maddaluna sold 10,000 shares of Pfizer stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $33.00, for a total transaction of $330,000.00. Following the completion of the transaction, the insider now directly owns 112,087 shares in the company, valued at $3,698,871. The disclosure for this sale can be found here. 0.07% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Nelson Roberts Investment Advisors LLC boosted its stake in Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 189 shares during the period. Stelac Advisory Services LLC bought a new stake in Pfizer during the second quarter valued at $110,000. First National Bank Sioux Falls boosted its stake in Pfizer by 108.2% in the third quarter. First National Bank Sioux Falls now owns 3,367 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 1,750 shares during the period. Tuttle Tactical Management LLC bought a new stake in Pfizer during the second quarter valued at $117,000. Finally, Cornerstone Advisors Inc. boosted its stake in Pfizer by 17.4% in the third quarter. Cornerstone Advisors Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 541 shares during the period. 69.48% of the stock is currently owned by institutional investors.

About Pfizer

Related posts

Leave a Comment